Pappas Capital, a life science venture capital firm, announced today that its new fund, Pappas Ventures V, recently invested in OrphoMed, a clinical stage company that is developing best-in-class therapies for treatment of inadequately-controlled gastrointestinal disorders. The investment in OrphoMed is the first investment by the new Pappas Ventures fund.
{iframe}http://www.prnewswire.com/news-releases/new-pappas-capital-fund-makes-first-investment-300463377.html{/iframe}